Prednisolone Acetate
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Prednisolone Acetate: Conjunctival folliculosis
One-Sentence Summary
Prednisolone acetate is a topical corticosteroid eye drop, marketed in Australia with phenylephrine as Prednefrin Forte. It is used for ocular inflammatory conditions such as uveitis, iridocyclitis and conjunctivitis. The TxGNN model predicts it may be effective for conjunctival folliculosis, but there are no clinical trials and no publications supporting this specific prediction (evidence level L5). Of the other predictions, papillary conjunctivitis and vernal conjunctivitis have indirect supporting evidence (L4).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Conjunctival folliculosis |
| TxGNN Prediction Score | 0.9974 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Other predictions reviewed (top 10): The top four predictions share the same score (0.9974) and have no supporting evidence. Papillary conjunctivitis (0.9972) and vernal conjunctivitis (0.9958) are the only predictions with trial or literature material, and both are rated L4 (“Research Question”).
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available. Based on known pharmacology, prednisolone acetate is a glucocorticoid. Topical glucocorticoids suppress ocular surface and intraocular inflammation. Its efficacy in uveitis and conjunctivitis is established, and mechanistically it may be applicable to other inflammatory conjunctival conditions.
For conjunctival folliculosis specifically, the link is weak. Folliculosis is typically a benign, often asymptomatic finding that rarely needs anti-inflammatory therapy, so the high model score does not translate into a clear clinical need.
Several other predictions are more plausible. Papillary and giant papillary conjunctivitis involve immune-mediated inflammation of the tarsal conjunctiva. Vernal keratoconjunctivitis is a chronic Th2- and mast cell-mediated allergic disease, and topical corticosteroids are an established treatment for severe flares. Serous non-viral conjunctivitis is likely a subtype of an existing indication rather than a true new use.
Some predictions are clinically doubtful. Acute hemorrhagic conjunctivitis is a self-limiting viral infection where steroids may prolong viral shedding. Parasitic conjunctivitis would need concurrent antiparasitic therapy. Postinfectious vasculitis is systemic, and this product has minimal systemic exposure.
Clinical Trial Evidence
No clinical trials are registered for the top predicted indication (conjunctival folliculosis).
Trials found for lower-ranked predictions:
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT01437982 | Phase 4 | Completed | 140 | Post-marketing safety surveillance of loteprednol etabonate 0.5% (a different corticosteroid); papillary conjunctivitis. Indirect, class-level information only |
| NCT04705584 | NA | Unknown | 180 | Cyclosporine A 2% vs tacrolimus 0.3% in resistant spring catarrh (vernal conjunctivitis) as alternatives to steroids; a prednisolone arm is not confirmed |
No ANZCTR identifiers were found in the data compiled for this report.
Literature Evidence
No literature is available for conjunctival folliculosis. The most relevant publications for other predicted indications are below.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 24055903 | 2013 | Experimental comparison | Cornea | Compared cyclosporine A, epinastine and prednisolone acetate 1% in an experimental allergic conjunctivitis model (vernal/allergic) |
| 12931748 | 2003 | Cohort | Asian Pac J Allergy Immunol | Treatment outcomes in Thai patients with vernal keratoconjunctivitis; severe cases received topical corticosteroids |
| 26984315 | 2016 | Review | Adv Ther | Intraocular pressure effects of topical loteprednol etabonate; class safety information |
| 18020605 | 1998 | Review | BioDrugs | Loteprednol etabonate in ocular inflammation (class-level) |
| 9713785 | 1998 | Clinical study | J Glaucoma | Intraocular pressure change during long-term loteprednol use |
| 15523196 | 2004 | Review | Curr Opin Ophthalmol | Ocular manifestations and management of graft-versus-host disease (pseudomembranous conjunctivitis) |
| 32621983 | 2020 | Case report | J AAPOS | Mycoplasma-induced rash and mucositis with pseudomembrane; treated with topical prednisolone acetate among other agents |
| 21434554 | 2011 | Case report | Indian J Tuberc | Conjunctival tuberculosis initially misdiagnosed as allergic conjunctivitis and given prednisolone acetate 1% without improvement |
| 29260110 | 2017 | Case series | Am J Ophthalmol Case Rep | Surgical excision for medically refractory giant papillary conjunctivitis |
| 18724159 | 2008 | Case report | Cornea | Papillary conjunctivitis associated with Kikuchi disease |
None of these publications is a randomised trial of prednisolone acetate in the predicted indications. Most concern a different corticosteroid or are case-level reports.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 11908R | Prednefrin Forte | Eye drops containing prednisolone acetate 10 mg with phenylephrine hydrochloride 1.2 mg per mL, 10 mL | Not stated in the data compiled |
The product is a single-ingredient-class steroid combined with a vasoconstrictor (phenylephrine), administered by the ophthalmic route.
Safety Considerations
The knowledge graph lists the following conditions as contraindications or cautions for prednisolone acetate (drawn from graph edges, not label text):
- Ocular: herpes simplex virus keratitis, open-angle glaucoma, ocular hypertension, eye infectious disease, viral eye infection, fungal infection of eye, ocular tuberculosis, corneal pigmentation, conjunctivitis (infective)
- Metabolic/systemic: diabetes mellitus, diabetic ketoacidosis, G6PD deficiency, glycogen storage disease, cystinuria, galactosemia
- Porphyrias: porphyria, inherited porphyria, porphyrin metabolism disease
Literature for the predicted indications highlights steroid-induced intraocular pressure elevation, a particular concern with prolonged use and in young patients (for example in vernal disease). Long-term steroid use also carries infection risk.
No drug interaction records were found. Please refer to the TGA-approved Product Information (PI) for full warnings, contraindications and interactions.
Conclusion and Next Steps
Decision: Hold
Rationale:
- The top prediction, conjunctival folliculosis, is supported only by the model score (L5). It has no trials or literature, and the condition rarely needs treatment, so clinical value is doubtful.
- Papillary conjunctivitis and vernal conjunctivitis are the more credible directions (L4, “Research Question”), but the available evidence concerns other drugs and does not directly test prednisolone acetate.
To proceed, the following is needed:
- Mechanism of action data
- TGA Product Information warnings and contraindications (the approved indication text is missing from the licence record)
- Direct comparative or randomised evidence of prednisolone acetate in vernal or papillary conjunctivitis
- An intraocular pressure and infection monitoring plan for any extended steroid use
- Confirmation of whether a steroid arm exists in NCT04705584
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.